<DOC>
	<DOC>NCT01964716</DOC>
	<brief_summary>This study will compare the immune responses of the infants who have been given 13vPnC in the mutidose vial formulation to the immune reponses of the infants who have been given 13vPnC in the single-dose syringe formulation. It will also evaluate the safety of 13-valent pneumococcal conjugate vaccine (13vPnC) in all infants who are vaccinated.</brief_summary>
	<brief_title>13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Aged 42 to 70 days at enrollment. Determined by medical history, physical examination, and clinical judgment to be eligible for the study Weight of 3.5 kg or greater at the time of enrollment Previous vaccination with licensed or investigational pneumococcal vaccine. A previous anaphylactic reaction to any vaccine or vaccinerelated component. Contraindication to vaccination with pneumococcal conjugate vaccine. Receipt of blood products or gammaglobulin since birth</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>70 Days</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Prevenar 13</keyword>
	<keyword>13vPnC</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>